I am a
Home I AM A Search Login

Papers of the Week

Papers: 3 Dec 2022 - 9 Dec 2022

2022 Dec 01

Clin Gastroenterol Hepatol

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.


Loftus EV, Colombel J-F, Takeuchi K, Gao X, Panaccione R, Danese S, Dubinsky M, Schreiber S, Ilo D, Finney-Hayward T, Zhou W, Phillips C, Sanchez Gonzalez Y, Shu L, Yao X, Zhou Q, Vermeire S
Clin Gastroenterol Hepatol. 2022 Dec 01.
PMID: 36464141.


We evaluated the efficacy of once daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative colitis (UC). Post hoc analyses were performed on pooled data from two replicate, phase 3, multicenter induction trials, U-ACHIEVE Induction and U-ACCOMPLISH, to determine the earliest timepoint of efficacy onset.